AACR 2021 | Mobocertinib for previously treated NSCLC with EFGR mutations

Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, discusses the use of the tyrosine kinase inhibitor (TKI) mobocertinib in patients with previously treated non-small cell lung cancer (NSCLC) who have EFGR exon 20 insertion mutations. A Phase I/II trial (NCT02716116) of mobocertinib in this patient population reported a preliminary response rate between 26% and 40%. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.